Related Experiment Video
Updated: Jun 28, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
CXCL10 blockade protects mice from cyclophosphamide-induced cystitis
Senthilkumar K Sakthivel1, Udai P Singh2, Shailesh Singh3
1Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA.
Journal of Immune Based Therapies and Vaccines
|October 30, 2008
Summary
Elevated CXCR3 ligands, including CXCL10, are linked to interstitial cystitis (IC). Blocking CXCL10 in mice reduced cystitis severity, suggesting chemokines as potential drug targets for this condition.
Area of Science:
- Immunology
- Urology
- Molecular Biology
Background:
- Interstitial cystitis (IC) is a chronic bladder condition with incompletely understood mechanisms.
- CXCR3 ligands and their role in inflammatory conditions are of growing interest.
Purpose of the Study:
- To investigate the role of CXCR3 ligands in interstitial cystitis.
- To explore the therapeutic potential of targeting CXCR3 ligands in a mouse model of cystitis.
Main Methods:
- Serum and tissue samples from IC patients and cyclophosphamide (CYP)-induced mouse cystitis models were analyzed.
- Expression levels of CXCR3, its ligands (CXCL9, CXCL10, CXCL11), and Th1 cytokines were quantified.
- Cellular infiltration (CD4+ T cells, mast cells, NK cells, NKT cells) was assessed.
- The effect of CXCL10 blockade on cystitis severity was evaluated in mice.
Main Results:
- Serum levels of CXCR3 ligands (CXCL9, CXCL10, CXCL11) were elevated in IC patients and correlated with CYP-induced cystitis in mice.
- Increased expression of CXCR3 ligands and Th1 cytokines was observed in the urinary bladder and lymph nodes of mice with cystitis.
- CYP treatment led to increased infiltration of T cells, mast cells, NK cells, and NKT cells.
- Blocking CXCL10 significantly attenuated the severity of CYP-induced cystitis.
Conclusions:
- CXCL10 is a key mediator in the pathogenesis of cystitis.
- Targeting CXCL10 may offer a novel therapeutic strategy for treating cystitis and related inflammatory conditions.